NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free PRAX Stock Alerts $54.54 +0.38 (+0.70%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$54.35▼$55.4450-Day Range$46.59▼$62.1852-Week Range$12.45▼$67.21Volume169,370 shsAverage Volume217,177 shsMarket Capitalization$933.18 millionP/E RatioN/ADividend YieldN/APrice Target$105.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Praxis Precision Medicines alerts: Email Address Praxis Precision Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside94.0% Upside$105.80 Price TargetShort InterestHealthy4.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($8.64) to ($9.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector597th out of 904 stocksPharmaceutical Preparations Industry279th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePraxis Precision Medicines has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.69% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 77.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRAX. Previous Next 2.5 News and Social Media Coverage News SentimentPraxis Precision Medicines has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Praxis Precision Medicines this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for PRAX on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($8.64) to ($9.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Praxis Precision Medicines Stock (NASDAQ:PRAX)Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Read More PRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRAX Stock News HeadlinesMay 4, 2024 | americanbankingnews.comXOMA (NASDAQ:XOMA) & Praxis Precision Medicines (NASDAQ:PRAX) Head-To-Head ContrastMay 3, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 3, 2024 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up to $54.87May 3, 2024 | americanbankingnews.comRobert W. Baird Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)May 1, 2024 | msn.comBaird Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform RecommendationApril 30, 2024 | msn.comGoldman Sachs revamps "high-quality" stock picks listApril 30, 2024 | msn.comBankrupt national retailer pins hopes on popular new serviceMay 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 28, 2024 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Receives "Buy" Rating from HC WainwrightApril 27, 2024 | americanbankingnews.comShort Interest in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Rises By 77.1%April 26, 2024 | tmcnet.comMedaptus and Banner Health Partner to Revolutionize Charge Processing with Charge Pro: Beyond Automation to Enhanced Efficiency and PrecisionApril 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)April 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)April 17, 2024 | msn.comWhy an ALS Drug Was Pulled From the MarketApril 12, 2024 | globenewswire.comPraxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingApril 5, 2024 | globenewswire.comPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 2, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | markets.businessinsider.comPraxis Precision Medicines Announces Pricing Of Underwritten Public OfferingMarch 28, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Pricing of $200 Million Public OfferingMarch 27, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Proposed Public OfferingMarch 26, 2024 | msn.comPraxis gains after mid-stage data for epilepsy candidateMarch 26, 2024 | markets.businessinsider.comPraxis Precision Medicines Reports Positive Results From PRAX-628 Study - Quick FactsMarch 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Praxis Precision Medicines’ PRAX-628 Based on Strong Clinical Trial Outcomes and Market PotentialMarch 26, 2024 | msn.comWhy Praxis Precision Medicines Stock Is Trading Higher TuesdayMarch 26, 2024 | finance.yahoo.comTop 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-HighMarch 26, 2024 | seekingalpha.comPraxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory FilingSee More Headlines Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/05/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRAX CUSIPN/A CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$105.80 High Stock Price Target$150.00 Low Stock Price Target$29.00 Potential Upside/Downside+94.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($23.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,280,000.00 Net Margins-5,037.88% Pretax Margin-5,037.88% Return on Equity-151.02% Return on Assets-115.60% Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Sales & Book Value Annual Sales$2.45 million Price / Sales380.89 Cash FlowN/A Price / Cash FlowN/A Book Value$7.92 per share Price / Book6.89Miscellaneous Outstanding Shares17,110,000Free Float16,646,000Market Cap$933.18 million OptionableOptionable Beta2.87 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Marcio Silva De'Souza M.B.A. (Age 44)President, CEO & Director Comp: $1.18MMr. Timothy Edwin Kelly (Age 50)CFO & Treasurer Comp: $691.58kMr. Alex Nemiroff J.D. (Age 44)General Counsel & Secretary Comp: $577.34kDr. Steven Petrou B.Sc. (Hons.)Ph.D., Co-Founder & Chief Scientific OfficerLauren MastrocolaVP of Finance & Principal Accounting OfficerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerAlex KaneVP of Investor Relations & Corporate CommunicationsMs. Kelly McCueChief People OfficerMs. Alyssa J. S. Wyant (Age 49)Chief Regulatory & Quality Officer Ms. Megan T. Sniecinski (Age 42)Chief Business Officer More ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULAurinia PharmaceuticalsNASDAQ:AUPHPliant TherapeuticsNASDAQ:PLRXBicycle TherapeuticsNASDAQ:BCYCPureTech HealthNASDAQ:PRTCView All CompetitorsInsiders & InstitutionsChase Investment Counsel CorpBought 3,768 shares on 5/2/2024Ownership: 0.022%BNP Paribas Financial MarketsBought 6,750 shares on 5/1/2024Ownership: 0.051%Simplex Trading LLCBought 1,000 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Bought 71,253 shares on 4/24/2024Ownership: 0.538%Windmill Hill Asset Management LtdBought 5,268 shares on 4/22/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions PRAX Stock Analysis - Frequently Asked Questions Should I buy or sell Praxis Precision Medicines stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares. View PRAX analyst ratings or view top-rated stocks. What is Praxis Precision Medicines' stock price target for 2024? 5 Wall Street research analysts have issued 12-month price targets for Praxis Precision Medicines' stock. Their PRAX share price targets range from $29.00 to $150.00. On average, they predict the company's share price to reach $105.80 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price. View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts. How have PRAX shares performed in 2024? Praxis Precision Medicines' stock was trading at $22.28 at the beginning of the year. Since then, PRAX stock has increased by 144.8% and is now trading at $54.54. View the best growth stocks for 2024 here. Are investors shorting Praxis Precision Medicines? Praxis Precision Medicines saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 763,900 shares, an increase of 77.1% from the March 31st total of 431,400 shares. Based on an average daily volume of 200,900 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.7% of the company's shares are sold short. View Praxis Precision Medicines' Short Interest. When is Praxis Precision Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRAX earnings forecast. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($2.97) EPS for the quarter, topping analysts' consensus estimates of ($3.05) by $0.08. The business earned $0.52 million during the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines had a negative net margin of 5,037.88% and a negative trailing twelve-month return on equity of 151.02%. What ETF holds Praxis Precision Medicines' stock? Invesco Dorsey Wright Healthcare Momentum ETF holds 25,144 shares of PRAX stock, representing 1.00% of its portfolio. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines shares reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.54%), PCG Wealth Advisors LLC (0.10%), BNP Paribas Financial Markets (0.05%), Windmill Hill Asset Management Ltd (0.04%), Chase Investment Counsel Corp (0.02%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Jill Desimone, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRAX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldCharles Payne Demystifies OptionsUnstoppable ProsperityThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.